{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:25:56Z","timestamp":1793190356062,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In the phase 3 Coronavirus Efficacy (COVE) trial (NCT04470427), post-dose two Ancestral Spike-specific binding (bAb) and neutralizing (nAb) antibodies were shown to be correlates of risk (CoR) and of protection against Ancestral-lineage COVID-19 in SARS-CoV-2 naive participants. In the SARS-CoV-2 Omicron era, Omicron subvariants with varying degrees of immune escape now dominate, seropositivity rates are high, and booster doses are administered, raising questions on whether and how these developments affect the bAb and nAb correlates. To address these questions, we assess post-boost BA.1 Spike-specific bAbs and nAbs as CoRs and as correlates of booster efficacy in COVE. For naive individuals, bAbs and nAbs inversely correlate with Omicron COVID-19: hazard ratios (HR) per 10-fold marker increase (95% confidence interval) are 0.16 (0.03, 0.79) and 0.31 (0.10, 0.96), respectively. In non-naive individuals the analogous results are similar: 0.15 (0.04, 0.63) and 0.28 (0.07, 1.08). For naive individuals, three vs two-dose booster efficacy correlates with predicted nAb titer at exposure, with estimates -8% (-126%, 48%), 50% (25%, 67%), and 74% (49%, 87%), at 56, 251, and 891 Arbitrary Units\/ml. These results support the continued use of antibody as a surrogate endpoint.<\/jats:p>","DOI":"10.1038\/s41467-024-52348-9","type":"journal-article","created":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T12:03:07Z","timestamp":1726056187000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Omicron COVID-19 immune correlates analysis of a third dose of mRNA-1273 in the COVE trial"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4381-1124","authenticated-orcid":false,"given":"Bo","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youyi","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Fintzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly E.","family":"Janes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avi","family":"Kenny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2106-0953","authenticated-orcid":false,"given":"Marco","family":"Carone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1019-8343","authenticated-orcid":false,"given":"David","family":"Benkeser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars W. P.","family":"van der Laan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiping","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honghong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwen","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenchen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavesh","family":"Borate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0374-6768","authenticated-orcid":false,"given":"Isabel","family":"Reeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0333-5925","authenticated-orcid":false,"given":"Lindsay N.","family":"Carpp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"Houchens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi","family":"Jayashankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuong","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6778-7253","authenticated-orcid":false,"given":"Carl J.","family":"Fichtenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0098-7995","authenticated-orcid":false,"given":"Spyros","family":"Kalams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3620-3059","authenticated-orcid":false,"given":"Cynthia L.","family":"Gay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele P.","family":"Andrasik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James G.","family":"Kublin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2179-2436","authenticated-orcid":false,"given":"Lawrence","family":"Corey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9480-2714","authenticated-orcid":false,"given":"Kathleen M.","family":"Neuzil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances","family":"Priddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rituparna","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethany","family":"Girard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0489-0074","authenticated-orcid":false,"given":"Hana M.","family":"El Sahly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1752-1926","authenticated-orcid":false,"given":"Lindsey R.","family":"Baden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6137-8312","authenticated-orcid":false,"given":"Ruben O.","family":"Donis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Koup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2662-9427","authenticated-orcid":false,"given":"Peter B.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4073-0393","authenticated-orcid":false,"given":"Dean","family":"Follmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"On behalf of the United States Government (USG) COVID-19 Immune Assays Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Moderna, Inc. Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Coronavirus Vaccine Prevention Network (CoVPN)\/Coronavirus Efficacy (COVE) Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"USG\/CoVPN Biostatistics Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars W. P.","family":"van der Laan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,11]]},"reference":[{"key":"52348_CR1","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403\u2013416 (2021).","journal-title":"N. Engl. J. Med."},{"key":"52348_CR2","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1056\/NEJMoa2113017","volume":"385","author":"HM El Sahly","year":"2021","unstructured":"El Sahly, H. M. et al. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. N. Engl. J. Med. 385, 1774\u20131785 (2021).","journal-title":"N. Engl. J. Med."},{"key":"52348_CR3","doi-asserted-by":"publisher","first-page":"eade9078","DOI":"10.1126\/scitranslmed.ade9078","volume":"15","author":"D Benkeser","year":"2023","unstructured":"Benkeser, D. et al. Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial. Sci. Transl. Med. 15, eade9078 (2023).","journal-title":"Sci. Transl. Med."},{"key":"52348_CR4","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1126\/science.abm3425","volume":"375","author":"PB Gilbert","year":"2022","unstructured":"Gilbert, P. B. et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science 375, 43\u201350 (2022).","journal-title":"Science"},{"key":"52348_CR5","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.3390\/v15102029","volume":"15","author":"Y Huang","year":"2023","unstructured":"Huang, Y. et al. Stochastic interventional vaccine efficacy and principal surrogate analyses of antibody markers as correlates of protection against symptomatic COVID-19 in the COVE mRNA-1273 trial. Viruses 15, 2029 (2023).","journal-title":"Viruses"},{"key":"52348_CR6","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ijid.2023.09.012","volume":"137","author":"NS Hejazi","year":"2023","unstructured":"Hejazi, N. S. et al. Stochastic interventional approach to assessing immune correlates of protection: Application to the COVE messenger RNA-1273 vaccine trial. Int J. Infect. Dis. 137, 28\u201339 (2023).","journal-title":"Int J. Infect. Dis."},{"key":"52348_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39292-w","volume":"14","author":"D Follmann","year":"2023","unstructured":"Follmann, D. et al. Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration. Nat. Commun. 14, 3605 (2023).","journal-title":"Nat. Commun."},{"key":"52348_CR8","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/s41591-022-01679-5","volume":"28","author":"R Pajon","year":"2022","unstructured":"Pajon, R. et al. Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trial. Nat. Med. 28, 823\u2013830 (2022).","journal-title":"Nat. Med."},{"key":"52348_CR9","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1056\/NEJMp2211314","volume":"387","author":"PB Gilbert","year":"2022","unstructured":"Gilbert, P. B. et al. A Covid-19 milestone attained\u2014a correlate of protection for vaccines. N. Engl. J. Med. 387, 2203\u20132206 (2022).","journal-title":"N. Engl. J. Med."},{"key":"52348_CR10","unstructured":"World Health Organization. Weekly epidemiological update on COVID-19\u201420 July 2022. [accessed 18 July 2023]. Available at: https:\/\/www.who.int\/publications\/m\/item\/weekly-epidemiological-update-on-covid-19-20-July-2022."},{"key":"52348_CR11","doi-asserted-by":"publisher","first-page":"1130539","DOI":"10.3389\/fimmu.2023.1130539","volume":"14","author":"S Pather","year":"2023","unstructured":"Pather, S. et al. SARS-CoV-2 Omicron variants: burden of disease, impact on vaccine effectiveness and need for variant-adapted vaccines. Front. Immunol. 14, 1130539 (2023).","journal-title":"Front. Immunol."},{"key":"52348_CR12","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1056\/NEJMc2119236","volume":"386","author":"A Rossler","year":"2022","unstructured":"Rossler, A., Riepler, L., Bante, D., von Laer, D. & Kimpel, J. SARS-CoV-2 Omicron variant neutralization in serum from vaccinated and convalescent persons. N. Engl. J. Med. 386, 698\u2013700 (2022).","journal-title":"N. Engl. J. Med."},{"key":"52348_CR13","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1056\/NEJMc2201607","volume":"386","author":"A Rossler","year":"2022","unstructured":"Rossler, A., Knabl, L., von Laer, D. & Kimpel, J. Neutralization profile after recovery from SARS-CoV-2 Omicron infection. N. Engl. J. Med. 386, 1764\u20131766 (2022).","journal-title":"N. Engl. J. Med."},{"key":"52348_CR14","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/s41586-022-04399-5","volume":"602","author":"JM Carreno","year":"2022","unstructured":"Carreno, J. M. et al. Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. Nature 602, 682\u2013688 (2022).","journal-title":"Nature"},{"key":"52348_CR15","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/s41586-021-04387-1","volume":"602","author":"S Cele","year":"2022","unstructured":"Cele, S. et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature 602, 654\u2013656 (2022).","journal-title":"Nature"},{"key":"52348_CR16","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41586-022-04980-y","volume":"608","author":"Y Cao","year":"2022","unstructured":"Cao, Y. et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature 608, 593\u2013602 (2022).","journal-title":"Nature"},{"key":"52348_CR17","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1056\/NEJMc2212117","volume":"387","author":"NP Hachmann","year":"2022","unstructured":"Hachmann, N. P., Miller, J., Collier, A. Y. & Barouch, D. H. Neutralization escape by SARS-CoV-2 Omicron subvariant BA.4.6. N. Engl. J. Med. 387, 1904\u20131906 (2022).","journal-title":"N. Engl. J. Med."},{"key":"52348_CR18","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1056\/NEJMra2206573","volume":"387","author":"DH Barouch","year":"2022","unstructured":"Barouch, D. H. Covid-19 vaccines\u2014immunity, variants, boosters. N. Engl. J. Med. 387, 1011\u20131020 (2022).","journal-title":"N. Engl. J. Med."},{"key":"52348_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32396-9","volume":"13","author":"K Khan","year":"2022","unstructured":"Khan, K. et al. Omicron BA.4\/BA.5 escape neutralizing immunity elicited by BA.1 infection. Nat. Commun. 13, 4686 (2022).","journal-title":"Nat. Commun."},{"key":"52348_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37176-7","volume":"14","author":"D Cromer","year":"2023","unstructured":"Cromer, D. et al. Predicting vaccine effectiveness against severe COVID-19 over time and against variants: a meta-analysis. Nat. Commun. 14, 1633 (2023).","journal-title":"Nat. Commun."},{"key":"52348_CR21","doi-asserted-by":"publisher","first-page":"e1004107","DOI":"10.1371\/journal.pmed.1004107","volume":"19","author":"I Bergeri","year":"2022","unstructured":"Bergeri, I. et al. Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: a systematic review and meta-analysis of standardized population-based studies. PLoS Med. 19, e1004107 (2022).","journal-title":"PLoS Med."},{"key":"52348_CR22","doi-asserted-by":"publisher","first-page":"601","DOI":"10.15585\/mmwr.mm7222a3","volume":"72","author":"JM Jones","year":"2023","unstructured":"Jones, J. M. et al. Estimates of SARS-CoV-2 seroprevalence and incidence of primary SARS-CoV-2 infections among blood donors, by COVID-19 vaccination status\u2014United States, April 2021\u2013September 2022. Morb. Mortal. Wkly Rep. 72, 601\u2013605 (2023).","journal-title":"Morb. Mortal. Wkly Rep."},{"key":"52348_CR23","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1001\/jama.2022.17876","volume":"328","author":"DY Lin","year":"2022","unstructured":"Lin, D. Y. et al. Association of primary and booster vaccination and prior infection with SARS-CoV-2 infection and severe COVID-19 outcomes. JAMA 328, 1415\u20131426 (2022).","journal-title":"JAMA"},{"key":"52348_CR24","doi-asserted-by":"publisher","first-page":"104475","DOI":"10.1016\/j.ebiom.2023.104475","volume":"89","author":"AP Underwood","year":"2023","unstructured":"Underwood, A. P. et al. Durability and breadth of neutralisation following multiple antigen exposures to SARS-CoV-2 infection and\/or COVID-19 vaccination. EBioMedicine 89, 104475 (2023).","journal-title":"EBioMedicine"},{"key":"52348_CR25","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/S1473-3099(22)00801-5","volume":"23","author":"N Bobrovitz","year":"2023","unstructured":"Bobrovitz, N. et al. Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression. Lancet Infect. Dis. 23, 556\u2013567 (2023).","journal-title":"Lancet Infect. Dis."},{"key":"52348_CR26","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1146\/annurev-immunol-101721-061120","volume":"41","author":"A Sette","year":"2023","unstructured":"Sette, A., Sidney, J. & Crotty, S. T cell responses to SARS-CoV-2. Annu Rev. Immunol. 41, 343\u2013373 (2023).","journal-title":"Annu Rev. Immunol."},{"key":"52348_CR27","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1126\/science.abg9175","volume":"372","author":"L Stamatatos","year":"2021","unstructured":"Stamatatos, L. et al. mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. Science 372, 1413\u20131418 (2021).","journal-title":"Science"},{"key":"52348_CR28","doi-asserted-by":"publisher","unstructured":"Goel, R. R. et al. Distinct antibody and memory B cell responses in SARS-CoV-2 naive and recovered individuals following mRNA vaccination. Sci. Immunol. 6, https:\/\/doi.org\/10.1126\/sciimmunol.abi6950 (2021).","DOI":"10.1126\/sciimmunol.abi6950"},{"key":"52348_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39816-4","volume":"14","author":"T Hertz","year":"2023","unstructured":"Hertz, T. et al. Correlates of protection for booster doses of the SARS-CoV-2 vaccine BNT162b2. Nat. Commun. 14, 4575 (2023).","journal-title":"Nat. Commun."},{"key":"52348_CR30","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1038\/s41591-023-02228-4","volume":"29","author":"DS Khoury","year":"2023","unstructured":"Khoury, D. S. et al. Predicting the efficacy of variant-modified COVID-19 vaccine boosters. Nat. Med 29, 574\u2013578 (2023).","journal-title":"Nat. Med"},{"key":"52348_CR31","doi-asserted-by":"crossref","unstructured":"Lumley, T. Complex Surveys: A Guide to Analysis Using R Vol. 565 (John Wiley & Sons, 2010).","DOI":"10.1002\/9780470580066"},{"key":"52348_CR32","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1093\/biostatistics\/kxac024","volume":"24","author":"PB Gilbert","year":"2023","unstructured":"Gilbert, P. B., Fong, Y., Kenny, A. & Carone, M. A controlled effects approach to assessing immune correlates of protection. Biostatistics 24, 850\u2013865 (2023).","journal-title":"Biostatistics"},{"key":"52348_CR33","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1111\/biom.13690","volume":"79","author":"L van der Laan","year":"2023","unstructured":"van der Laan, L., Zhang, W. & Gilbert, P. B. Nonparametric estimation of the causal effect of a stochastic threshold-based intervention. Biometrics 79, 1014\u20131028 (2023).","journal-title":"Biometrics"},{"key":"52348_CR34","doi-asserted-by":"crossref","first-page":"Article25","DOI":"10.2202\/1544-6115.1309","volume":"6","author":"MJ van der Laan","year":"2007","unstructured":"van der Laan, M. J., Polley, E. C. & Hubbard, A. E. Super learner. Stat. Appl Genet Mol. Biol. 6, Article25 (2007).","journal-title":"Stat. Appl Genet Mol. Biol."},{"key":"52348_CR35","doi-asserted-by":"publisher","unstructured":"Zhang, B. et al. Omicron COVID-19 immune correlates analysis of a third dose of mRNA-1273 in the COVE trial. Github. https:\/\/doi.org\/10.5281\/zenodo.13381578 (2024).","DOI":"10.5281\/zenodo.13381578"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-52348-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-52348-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-52348-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T12:05:12Z","timestamp":1726056312000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-52348-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,11]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["52348"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-52348-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.10.15.23295628","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,11]]},"assertion":[{"value":"26 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors have completed the ICMJE uniform disclosure form at\n                      \n                      and declare: W.D., H.Z., X.W., F.P., R.D., and B.G. are employed by Moderna Inc. and have stock or stock options in Moderna Inc. H.E.J. serves\/served as an unpaid member within the past 36 months as a DSMB member for a Phase II monkeypox vaccine study (DMID) and for a Phase I oral cholera vaccine study (DMID). M.C. reports an honorarium for service within the past 36 months on a grant review panel for the National Comprehensive Cancer Network and Pfizer. C.J.F. reports grants to his institution within the past 36 months from Gilead Sciences, ViiV Healthcare, and Merck, as well as payment for advisory board participation within the past 36 months from ViiV Healthcare and Theratechnologies, Inc. K.M.N. reports grants to her institution within the past 36 months from Pfizer to conduct clinical trials of COVID-19 vaccines, but K.M.N. receives no salary support from these grants. K.M.N. reports a grant from Vaxco within the past 36 months for phase 1 testing of a broadly reactive COVID-19 vaccine. F.P. was a member of the CEPI Scientific Advisory Board within the past 36 months and reports support from Moderna, Inc. for attending meetings and\/or travel within the past 36 months. Within the past 36 months, L.R.B. was involved in HIV and SARS-CoV-2 vaccine clinical trials conducted in collaboration with the NIH, HIV Vaccine Trials Network (HVTN), Covid Vaccine Prevention Network (CoVPN), International AIDS Vaccine Initiative (IAVI), Crucell\/Janssen, Moderna, Military HIV Research Program (MHRP), the Gates Foundation, and Harvard Medical School; as well as participated on a DSMB for the NIH and an AMDAC Committee for the FDA. P.B.G. served as an unpaid member of the Moderna Zika Vaccine Scientific Advisory Board within the past 36 months. All authors declare no other support from any commercial entity for the submitted work; no other financial relationships with any commercial entities that might have an interest in the submitted work in the past 36 months, and no other relationships or activities within the past 36 months that could appear to have influenced the submitted work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7954"}}